Computertomography-guided Wire Marking of the Liver

Sponsor
Medical University of Graz (Other)
Overall Status
Completed
CT.gov ID
NCT01457599
Collaborator
(none)
20
1
61
0.3

Study Details

Study Description

Brief Summary

The aim of the study is to evaluate if it is possible to mark with a wire colorectal hepatic metastases after complete response to a neoadjuvant chemotherapy.Primary the investigators want to investigate if the wire marking is a possibility to mark respectively to identify these lesions. Further the investigators want to evaluate how many patients with complete radiologic have complete histologic response in their specimen respectively in how many specimens in the definitive histology tumor cells are visible.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Computertomography-guided marking of colorectal liver metastases

Detailed Description

Colorectal Cancer is most common in western countries. In 2007 in Austria 4462 new colorectal cancers were diagnosed. The most common place of metastasis is the liver. Approximately 15% of patients have metastasis at time of diagnosis of primary tumor and further 50% will develop metastases in the further course of the disease.However only 10-25% of patients are candidates for liver resection. New chemotherapeutics, new targeted therapies with monoclonal antibodies and better surgical techniques improved response rates, resection rates and overall survival. Owing to improved response rates metastases in the liver partially respectively completely disappeared, so that these lesions are not more visible in apparative diagnostic like CT-scan and MRI.

The question is now what to do with this patients? In the literature there is no evidence how to manage these patients. Conservative management would lead to a reoccurrence of metastases in the liver. On the other side surgical management is difficult, because metastases are preoperatively and intraoperatively not visible and resection is only possible with the removement of greater amounts of healthy tissue.

The computer tomography-guided wire marking of the metastases in the liver is a possibility to overcome these problems. All patients with complete radiologic response of metastases in the liver and metastases ≤ 1 cm are included in the study (RECISTE-Criteria). On day of surgical procedure patients will brought to interventional radiologist and based on computer tomography images before neoadjuvant chemotherapy the lesions will be marked computer tomography-guided with a wire(X-Reidy Breast Lesion Localization Needle, Cook Medical). The wire is placed percutaneously and under antibiotic prophylaxis. After the marking procedure, the patient is brought into the operating room to resect the metastases in the liver.

Study Design

Study Type:
Observational
Actual Enrollment :
20 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Computertomography-guided Wire Marking of Colorectal Hepatic Metastases After Complete Response to Neoadjuvant Chemotherapy. A Pilot Study
Study Start Date :
Jul 1, 2011
Actual Primary Completion Date :
Aug 1, 2016
Actual Study Completion Date :
Aug 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Marking Liver

Procedure: Computertomography-guided marking of colorectal liver metastases
Computertomography-guided marking of colorectal liver metastases

Outcome Measures

Primary Outcome Measures

  1. Sensitivity [One Year]

    Sensitivity of wire marking to find liver metastases with complete response to neoadjuvant chemotherapy

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Histologic verified cancer of the colon and rectum with metastases into the liver

  • Neoadjuvant chemotherapy with complete radiologic response of metastases in apparative diagnostic respectively metastases with a diameter ≤ 1 cm.

  • Technically Resectability

  • Age ≥ 18 Years

  • Written informed consent

Exclusion Criteria:
  • Age < 18 Years

  • Technically Irresectability

  • Neoadjuvant chemotherapy and response of metastases, however with a diameter > 1 cm.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Surgery Graz Styria Austria 8036

Sponsors and Collaborators

  • Medical University of Graz

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kornprat Peter, MD, MD, Medical University of Graz
ClinicalTrials.gov Identifier:
NCT01457599
Other Study ID Numbers:
  • INS-621000-0274-002
First Posted:
Oct 24, 2011
Last Update Posted:
Aug 16, 2016
Last Verified:
Aug 1, 2016
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Keywords provided by Kornprat Peter, MD, MD, Medical University of Graz
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2016